Saturday, May 21, 2022

Axios Pro Rata: "Renewed discipline" on seed cash 💸

Plus: Meme du jour | Saturday, May 21, 2022
 
Axios Open in app View in browser
 
Presented By Cooley
 
Axios Pro Rata
By Kia Kokalitcheva · May 21, 2022

Hello there! Welcome to an unusually (mercifully?) brief edition to our Saturday newsletter, as I was with other Axions at our retreat in D.C. this week.

  • 🚨 Reminder: Feel free to send me tips or comments by replying to this email or on Twitter @imkialikethecar.

Today's newsletter is 481 words, a 2-minute read.

 
 
1 big thing: Waiting for the shoe to drop on seed money
Illustration of money in the shape of downward pointing arrows.

Illustration: Shoshana Gordon/Axios

 

Seed-stage startups have been largely isolated, at least so far, from the stock market downturn, but some VCs tell Axios they're expecting that market to compress soon enough.

Why it matters: The pandemic's startup boom led to frothy fundraising for companies at all stages. But with the broader market dangling near bear territory, the money could be less abundant.

The big picture: The seed-stage market has been flooded by investors with capital, a welcome dynamic during the boom of the last two years.

  • And according to data from AngelList, median post-money valuations for pre-seed and seed deals have even slightly increased overall between January and April of this year.
  • Yet, anecdotally, VCs are beginning to see some of the more irrationally high fundraising terms of previous years disappear, especially as the market retrenches.

What they're saying: "Deployment has slowed down in anticipation of lower valuations, but some of that is a factor of seed founders realizing the new environment and delaying their raise," explains Hash3 Capital Fund general partner Hootan Rashidifard, who previously invested in seed startups at Canaan Partners.

  • "At the end of the day, innovation doesn't stop, but there is a renewed discipline around valuation because seed investors are cognizant of downstream valuation expectations."
  • Earlier this week, even famed startup accelerator Y Combinator warned its portfolio — including those still at the seed stage— that the fundraising market will be rough for the next six to 12 months.

Between the lines: VCs may have paid those high valuations over the last two years, but they're sure glad to wait a bit to see them come down to the more realistic level they believe they should have been at all along.

  • "No more $10 million [funding rounds] on $100 million [valuation] cap for a pre-revenue Mexican fintech," Salkantay Ventures partner Luis Daniel Arbulú, whose firm invests in Latin America, tells Axios.

Yes, but: The evergreen caveat is that regardless of market conditions, great companies will be in high demand from investors, and will continue to command high valuations and friendly terms.

  • "From what we're seeing, the top seed deals that we are interested in investing in are still very competitive and very competitively priced and we don't expect those prices to come down," Position Capital managing partner Jenny He tells Axios.

The bottom line: While some segments of the startup market are more immune than others, no one will be fully spared, especially the longer this market correction continues.

Share on Facebook Tweet this Story Post to LinkedIn Email this Story
 
 
📚 Due Diligence
Share on Facebook Tweet this Story Post to LinkedIn Email this Story
 
 
🧩 Double identity

In lieu of trivia this week, I'll leave you with a popular meme that immediately popped into my mind earlier this week, as I pondered the strategy VCs are playing in anticipation of a new pricing regime....

              Credit: Giphy

Share on Facebook Tweet this Story Post to LinkedIn Email this Story
 
 

A message from Cooley

Venture financing environment favors technology companies in Q1
 
 

After a record-breaking year, the first quarter of 2022 continued to reflect strong growth for tech companies. Of all Cooley deals, the volume of deals with pre-money valuations above $100 million remained high.

Get the latest data on the Cooley GO venture financing dashboard.

 
 
🧮 Final Numbers
Data: AngelList. Chart: Dani Alberti/Axios
Share on Facebook Tweet this Story Post to LinkedIn Email this Story
 
 

A message from Cooley

Cooley's Life Sciences & Healthcare Innovation Hub
 
 

Life sciences and health care leaders worldwide rely on Cooley for up-to-date, relevant and on-demand resources they need to successfully navigate a company's entire life cycle.

Visit the hub for thought leadership and the latest info on trending business and legal topics.

 

🙏 Thanks for reading! See you on Monday for Pro Rata's weekday programming, and please ask your friends, colleagues, and presentation deck designers to sign up.

Axios Pro
Go deeper with Axios Pro: Deals, featuring hyper-relevant news and analysis across PE, VC and M&A.
 

Axios thanks our partners for supporting our newsletters. If you're interested in advertising, learn more here.
Sponsorship has no influence on editorial content.

Axios, 3100 Clarendon B‌lvd, Suite 1300, Arlington VA 22201
 
You received this email because you signed up for newsletters from Axios.
Change your preferences or unsubscribe here.
 
Was this email forwarded to you?
Sign up now to get Axios in your inbox.
 

Follow Axios on social media:

Axios on Facebook Axios on Twitter Axios on Instagram
 
 
                                             

No comments:

Post a Comment

Why It's Time to Hope

The stench of the Nifty Fifty... The destructive power of human nature... 'A big economic boom'... Milei's chain saw comes to ...